OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skin care, notes the announcement (14 June 2022) by ProBiotix Health plc

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skin care, notes the announcement (14 June 2022) by ProBiotix Health plc
GSTechnologies Limited (LSE: GST), the fintech and information technology solutions company, is pleased to announce that the Financial Conduct Authority (“FCA”) has approved the change of control of Angra Limited
Blockchain technology is no longer constrained to the crypto ecosystem, as study has shown its potential for involvement in the healthcare industry.
Iron ore is experiencing a rally that has been largely driven by two factors that are yet to occur: a renewed Chinese building boom and supply disruptions in Australia, which
If the complex regulations of the crypto hub fail, it could cause damage to Territory’s financial industry and diplomatic sanctions
The 2021 breakout year for digital assets saw prices rise and prices explode, but there’s more.
GSTechnologies Limited (LSE: GST), the fintech and information technology solutions company, is pleased to announce the appointment of Mr. Tan Guan Han, Shayne (“Shayne Tan”) , an existing Executive Director,
GSTechnologies Limited (LSE: GST), the fintech and information technology solutions company, is pleased to announce the appointment of Mr Bai GuoJin (“Jack Bai”) , an existing Executive Director, as the
Singapore is now home to the LSEG Labs network’s new sustainable finance innovation unit, focused on accelerating activity in the country’s fintech ecosystem.
OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skin care, announces that its wholly-owned subsidiary, ProBiotix Health Ltd, has extended
OptiBiotix Health plc, a life sciences business developing compounds to tackle obesity, cardiovascular disease and diabetes,provides the following unaudited preliminary revenue figures for the first six months ended 30 June